Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Nikolaou A, Ambavane A, Shah A, Ma W, Tosh J, Kapetanakis V, Willson J, Wang F, Hogea C, Gorsh B, Gutierrez B, Sapra S, Suvannasankha A, Samyshkin Y. Nikolaou A, et al. Among authors: gorsh b. Expert Rev Hematol. 2021 Dec;14(12):1137-1145. doi: 10.1080/17474086.2021.1970522. Epub 2021 Sep 20. Expert Rev Hematol. 2021. PMID: 34465265
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T, Popat R, Suvannasankha A, Sarri G, Hughes R, Wang F, Hogea C, Ferrante SA, Gorsh B, Willson J, Kapetanakis V. Prawitz T, et al. Among authors: gorsh b. Adv Ther. 2021 Nov;38(11):5501-5518. doi: 10.1007/s12325-021-01884-7. Epub 2021 Sep 24. Adv Ther. 2021. PMID: 34561812 Free PMC article.
Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
Bessou A, Colin X, De Nascimento J, Sopwith W, Ferrante S, Gorsh B, Gutierrez B, Sansbury L, Willson J, Sapra S, Paka P, Wang F. Bessou A, et al. Among authors: gorsh b. Eur J Health Econ. 2023 Apr;24(3):321-333. doi: 10.1007/s10198-022-01463-9. Epub 2022 May 25. Eur J Health Econ. 2023. PMID: 35610398 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36164176
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. Nooka AK, et al. Among authors: gorsh b. Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. Epub 2023 Aug 25. Cancer. 2023. PMID: 37622738 Free PMC article.
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
Popat R, Lonial S, Voorhees PM, Esposti SD, Gorsh B, Gupta I, Opalinska J, Sapra S, Piontek T, He Z, Kleinman D, Schaumberg D, Regnault A, Meunier J, Eliason L. Popat R, et al. Among authors: gorsh b. J Adv Pract Oncol. 2023 Sep;14(6):503-518. doi: 10.6004/jadpro.2023.14.6.4. Epub 2023 Sep 1. J Adv Pract Oncol. 2023. PMID: 37808071 Free PMC article.
28 results